Veracyte Inc reports results for the quarter ended June 30 - Earnings Summary

• Veracyte Inc VCYT.OQ reported a quarterly adjusted loss of 1 cent​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 7 cents. The mean expectation of twelve analysts for the quarter was for earnings of 10 cents per share. Wall Street expected results to range from 5 cents to 14 cents per share.

• Revenue rose 13.8% to $130.16 million from a year ago; analysts expected $120.66 million.

• Veracyte Inc's reported EPS for the quarter was a loss of 1 cent​.

• The company reported a quarterly loss of $980 thousand.

• Veracyte Inc shares had fallen by 7.5% this quarter and lost 36.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 42% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Veracyte Inc is $43.00, about 41.8% above its last closing price of $25.01

This summary was machine generated from LSEG data August 6 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)